The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Effects of the 11β-Hydroxysteroid Dehydrogenase Inhibitor Carbenoxolone on Insulin Sensitivity in Men with Type 2 Diabetes
Abstract
11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) regenerates cortisol from inactive cortisone in liver and adipose tissue. Inhibition of 11 beta-HSD1 offers a novel potential therapy to lower intracellular cortisol concentrations and thereby enhance insulin sensitivity and hepatic lipid catabolism in type 2 diabetes, obesity, and hyperlipidemia. We evaluated this approach using the nonselective 11 beta-HSD inhibitor, carbenoxolone, in healthy men and lean male patients with type 2 diabetes. Six diet-controlled nonobese diabetic patients with hemoglobin A(1c) less than 8%, and six matched controls participated in a double-blind, cross-over comparison of carbenoxolone (100 mg every 8 h, orally, for 7 d) and placebo. They were admitted overnight for infusions of insulin (as required to maintain arterialized plasma glucose of 5.0 mM) and [13C6]glucose. Glucose kinetics were measured in the fasted state from 0700-0730 h, during a 3-h euglycemic hyperinsulinemic clamp (including somatostatin infusion and replacement of physiological GH and glucagon levels), and during a 2-h euglycemic hyperinsulinemic clamp with a 4-fold increase in glucagon levels. Data are the mean +/- SEM. Carbenoxolone had the expected effects of raising blood pressure and lowering plasma potassium. Carbenoxolone reduced total cholesterol in healthy subjects (5.25 +/- 0.34 vs. 4.78 +/- 0.40 mM; P < 0.01), but had no effect on other serum lipids or on cholesterol in diabetic patients. Carbenoxolone did not affect the rate of glucose disposal or the suppression of free fatty acids during hyperinsulinemia. However, carbenoxolone reduced the glucose production rate during hyperglucagonemia in diabetic patients (1.90 +/- 0.2 vs. 1.53 +/- 0.3 mg/kg x min; P < 0.05). This was attributable to reduced glycogenolysis (1.31 +/- 0.2 vs. 1.01 +/- 0.2 mg/kg x min; P < 0.005) rather than altered gluconeogenesis. These observations reinforce the potential metabolic benefits of inhibiting 11 beta-HSD1 in the liver of patients with type 2 diabetes. Further studies in obesity and hyperlipidemia are now warranted. However, clinically useful therapeutic effects will probably require selective 11 beta-HSD1 inhibitors that lower intraadipose cortisol levels and enhance peripheral glucose uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A transgenic model of visceral obesity and the metabolic syndrome
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N. M., Mullins, J. J., Seckl, J. R., & Flier, J. S. (2001) · Science · doi:10.1126/science.1066285 · Cited by 1,766 · cited 1×
“Conversely, mice with transgenic overexpression of 11 -HSD1 selectively in adipose tissue under the aP2 promoter have increased intraadipose glucocorticoid concentrations despite no change in plasma levels (5).”
BackgroundMineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated
Funder, J. W., Pearce, P. T., Smith, R., & Smith, A. I. (1988) · Science · doi:10.1126/science.2845584 · Cited by 1,628
Edwards, C. R. W., Burt, D., Mcintyre, M. A., De Kloet, E. R., Stewart, P. M., Brett, L., Sutanto, W. S., & Monder, C. (1988) · The Lancet · doi:10.1016/s0140-6736(88)90742-8 · Cited by 1,068
Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with Troglitazone
Nolan, J. J., Ludvik, B., Beerdsen, P., Joyce, M., & Olefsky, J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411033311803 · Cited by 926
Kotelevtsev, Y., Holmes, M. C., Burchell, A., Houston, P. M., Schmoll, D., Jamieson, P., Best, R., Brown, R., Edwards, C. R. W., Seckl, J. R., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14924 · Cited by 858
Stewart, P., Valentino, R., Wallace, A. M., Burt, D., Shackleton, C. L., & Edwards, C. W. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91014-2 · Cited by 803
Does central obesity reflect “Cushing's disease of the omentum”?
Bujalska, I. J., Kumar, S., & Stewart, P. M. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11222-8 · Cited by 753 · cited 1×
“been coined Cushing’s disease of the omentum (9).”
BackgroundGlucocorticoids and insulin resistance: old hormones, new targets
ANDREWS, R. C., & WALKER, B. R. (1999) · Clinical Science · doi:10.1042/cs0960513 · Cited by 731 · cited 2×
“Glucocorticoids have complex effects on glycogenic and glycogenolytic enzymes, which predict increased turnover and amplification of the effect of other signals (32, 33).”
BackgroundSelf-citationSeckl, J. R., & Walker, B. R. (2001) · Endocrinology · doi:10.1210/endo.142.4.8114 · Cited by 714
Self-citationDose-response characteristics for effects of insulin on production and utilization of glucose in man
Rizza, R. A., Mandarino, L. J., & Gerich, J. E. (1981) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1981.240.6.e630 · Cited by 703
Cited by
11β-Hydroxysteroid dehydrogenase type 1: a tissue specific regulator of glucocorticoid response
Tomlinson, J. W., Walker, E. A., Bujalska, I. J., Draper, N., Lavery, G. G., Cooper, M. S., Hewison, M., & Stewart, P. M. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0031 · Cited by 969
“effect on hepatic gluconeogenesis (200).”
11β-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action
Chapman, K., Holmes, M., & Seckl, J. (2013) · Physiological Reviews · doi:10.1152/physrev.00020.2012 · Cited by 887
Pathogenesis of non-alcoholic fatty liver disease
Dowman, J. K., Tomlinson, J. W., & Newsome, P. N. (2010) · QJM · doi:10.1093/qjmed/hcp158 · Cited by 741
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
Morton, N. M., Paterson, J. M., Masuzaki, H., Holmes, M. C., Staels, B., Fievet, C., Walker, B. R., Flier, J. S., Mullins, J. J., & Seckl, J. R. (2004) · Diabetes · doi:10.2337/diabetes.53.4.931 · Cited by 512
Self-citationMechanisms of Glucocorticoid-Induced Insulin Resistance
Geer, E. B., Islam, J., & Buettner, C. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.10.005 · Cited by 392
Macfarlane, D. P., Forbes, S., & Walker, B. R. (2008) · Journal of Endocrinology · doi:10.1677/joe-08-0054 · Cited by 385
“Journal of Endocrinology (2008) 197, 189–204 diabetes and lean volunteers improved hepatic insulin sensitivity measured by euglycaemic hyperinsulinaemic clamp (Walker et al. 1995, Andrews et al. 2003), although no effect was seen in non-diabetic obese individuals (Sandeep et al. 2005).”
BackgroundSelf-citationSheng, H., & Sun, H. (2011) · Natural Product Reports · doi:10.1039/c0np00059k · Cited by 289
The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome
Wang, M. (2005) · Nutrition & Metabolism · doi:10.1186/1743-7075-2-3 · Cited by 277
Alberts, P., Nilsson, C., Selén, G., Engblom, L. O. M., Edling, N. H. M., Norling, S., Klingström, G., Larsson, C., Forsgren, M., Ashkzari, M., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0344 · Cited by 263
11β-Hydroxysteroid dehydrogenases and the brain: From zero to hero, a decade of progress
Wyrwoll, C. S., Holmes, M. C., & Seckl, J. R. (2011) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.12.001 · Cited by 244
Glucocorticoids and 11beta-Hydroxysteroid Dehydrogenase in Adipose Tissue
Seckl, J. R. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.359 · Cited by 239
“Stable isotope glucose tracers have been used to demonstrate that, in lean patients with type 2 diabetes, carbenoxolone inhibits hepatic glucose production (Andrews et al., 2003).”
11β-hydroxysteroid dehydrogenase 1: translational and therapeutic aspects
Gathercole, L. L., Lavery, G. G., Morgan, S. A., Cooper, M. S., Sinclair, A. J., Tomlinson, J. W., & Stewart, P. M. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1050 · Cited by 196
11β-hydroxysteroid dehydrogenases: changing glucocorticoid action
Seckl, J. R. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.09.001 · Cited by 185
Bujalska, I. J., Draper, N., Michailidou, Z., Tomlinson, J. W., White, P. C., Chapman, K. E., Walker, E. A., & Stewart, P. M. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01718 · Cited by 165
Novel agents for the treatment of type 2 diabetes
DeFronzo, R. A., Triplitt, C. L., Abdul-Ghani, M., & Cersosimo, E. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.100 · Cited by 83
Gambineri, A., Vicennati, V., Genghini, S., Tomassoni, F., Pagotto, U., Pasquali, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2222 · Cited by 75
Self-citation11β-Hydroxysteroid dehydrogenase: unexpected connections
Walker, E. A., & Stewart, P. M. (2003) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(03)00134-6 · Cited by 72
Stimson, R. H., Andrew, R., McAvoy, N. C., Tripathi, D., Hayes, P. C., & Walker, B. R. (2011) · Diabetes · doi:10.2337/db10-0726 · Cited by 67
Self-citationKetoconazole enantiomer for the treatment of diabetes mellitus
Arakaki, R., & Welles, B. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903381411 · Cited by 21
Metadata
- Authors
- Andrews, R. C., Rooyackers, O., & Walker, B. R.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-01
- Volume
- 88
- Issue
- 1
- Pages
- 285-291
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2150654293
- Cited by
- 266
- References
- 37
- FWCI
- 13.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.